Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 05 2022 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
April 2022
Commission File Number: 0001723069
Tiziana Life
Sciences LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive
office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On April 5, 2022, Tiziana Life Sciences LTD (the “Company”)
issued a news service announcement in the United States announcing that the FDA Grants Permission to Enroll up to 8 Additional Secondary
Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab.
The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
TIZIANA LIFE SCIENCES LTD |
|
|
|
|
Date: April 5, 2022 |
By: |
/s/ Kunwar Shailubhai |
|
|
Name: |
Kunwar Shailubhai |
|
|
Title: |
Chief Executive Officer |
EXHIBIT INDEX
3
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2023 to Jul 2024